Melanotan II: Melanocortin Pharmacology and the Case Literature

Melanotan II is a cyclic heptapeptide written Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Read from the outside in, it is an acetylated N-terminus, a norleucine, then a ring closed by an amide bond - a lactam bridge - between an aspartate side chain and a lysine side chain, with a C-terminal amide. Its molecular formula is C50H69N15O9 and its mass is 1024.2 g/mol.

The sequence inside the ring is not arbitrary. His-Phe-Arg-Trp is the core message sequence of α-melanocyte-stimulating hormone, the endogenous peptide that signals through the melanocortin receptors. Melanotan II is a conformationally constrained mimic of that message: the lactam bridge holds the four critical residues in a fixed geometry, and the phenylalanine is replaced by its D-enantiomer.

Both modifications are standard medicinal-chemistry moves with predictable consequences. Cyclisation and D-amino acid substitution slow enzymatic degradation and reduce the entropic cost of receptor binding, which is why the analogue is substantially more potent and longer-lived than native α-MSH. Neither modification does anything to improve selectivity, and that is the central fact about this molecule.

There are five melanocortin receptors in humans, all G protein-coupled and all signalling principally through Gs and adenylyl cyclase to raise intracellular cAMP. They are anatomically and functionally distinct: MC1R sits on melanocytes and governs the eumelanin-versus-pheomelanin switch; MC2R is the adrenal ACTH receptor; MC3R and MC4R are expressed in the central nervous system, with MC4R central to energy-balance signalling; MC5R is found on exocrine tissue including sebaceous glands.

Melanotan II is an agonist at MC1R, MC3R, MC4R and MC5R. It does not meaningfully discriminate between them. This is why it is a useful tool compound in melanocortin pharmacology - a broad agonist is exactly what you want when probing which receptor mediates which effect - and simultaneously why its effects in an intact organism cannot be partitioned. Activating MC1R and activating MC4R are not independent events when a single non-selective ligand is present.

The human studies reported by Wessells and colleagues in 2000 illustrate this directly. Alongside the effect they were measuring, the investigators recorded nausea, flushing and yawning - a symptom cluster consistent with central melanocortin activation rather than with anything happening at melanocytes. The pharmacology predicts this, and the human record confirms it.

The indexed human literature on Melanotan II itself is small and old. The early-phase work from around 2000, including the Wessells studies, remains the substantive human dataset. There is no published Phase 3 programme, no long-term cohort, no carcinogenicity study and no characterised human pharmacokinetics in the modern literature.

Melanotan II is not approved by Health Canada, the FDA, the EMA, the TGA or any other regulator, for any indication. That is not a pending status or a paperwork gap - the molecule was never taken through a development programme that could produce an approval. Regulators in several jurisdictions have instead issued consumer warnings about unauthorised supply.

This has a knock-on effect on the safety literature that is easy to miss. Because supply is unregulated, the material that people were exposed to in the published case reports was, in general, of unverified identity and purity. Reviewers have flagged this repeatedly. It cuts both ways: it weakens attribution of any specific harm to the peptide, and it means the exposures described in the literature are not a clean model of the pure compound either.

This is the part of the Melanotan II record that carries the most weight, and it should be stated plainly rather than hedged. Beginning in 2009, dermatology journals published case reports of melanocytic lesion change following melanotan use. Cousen and colleagues, writing in the British Journal of Dermatology, described eruptive melanocytic naevi - new pigmented lesions appearing over a short interval. Subsequent authors reported dermoscopic changes in pre-existing naevi during use.

The reports then escalated in severity. In 2014, Hjuler and Lorentzen published a case of melanoma associated with the use of Melanotan II in Dermatology. Other reports of melanotan-associated melanoma have appeared in the dermatological literature from independent groups in different countries. The 2017 review by Habbema and colleagues in the International Journal of Dermatology assembled this material and found pigmented-lesion change to be the recurring theme across the α-MSH analogue reports.

What this evidence can and cannot support needs to be stated precisely. Case reports establish that an event occurred in temporal association with an exposure. They cannot establish incidence, relative risk, or causation, and there is no cohort or case-control study of Melanotan II users that could. The counter-consideration is real too: people who use tanning peptides may have other melanoma risk factors, and ascertainment is biased toward the cases that get written up.

That said, the mechanism is not neutral. MC1R agonism acts directly on melanocytes and drives melanogenesis, so a signal in melanocytic lesions is precisely where a non-selective melanocortin agonist would be expected to produce one if it produced one at all. The literature reports a coherent signal at the ceiling of evidence available for an unapproved compound, and no study exists that has looked harder and found nothing.

Melanotan II has an approved relative, and the relationship is instructive. Bremelanotide, also known as PT-141, arose from melanocortin work in the same lineage and is effectively a narrowed version of the same chemistry, shifted toward MC4R rather than acting across the whole receptor family.

Bremelanotide was developed formally, tested in randomised controlled trials, and approved in the United States in 2019 for hypoactive sexual desire disorder in premenopausal women. The 2020 systematic review by Mayer and Lynch summarises that programme and its evidence base.

The contrast is the point. A melanocortin agonist can be characterised, trialled and licensed. What distinguishes bremelanotide from Melanotan II is not exotic chemistry but receptor selectivity and the existence of a controlled development programme. Melanotan II remains a non-selective research tool with a small, dated human record and an adverse-event literature made of case reports.